Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulapualide a
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
01
Overview
Ulapualide A is a naturally occurring marine macrolide isolated from the egg masses of certain nudibranchs. It belongs to the class of trisoxazole-based macrolides and is structurally characterized as a diterpene lactone. Ulapualide A exhibits potent antitumor activity and acts as an actin-depolymerizing agent, disrupting cytoskeletal integrity in cells. Its mechanism involves binding to actin filaments and promoting their depolymerization, which leads to profound effects on cell adhesion and morphology. The compound has been studied for its unique stereochemistry and structure-activity relationships with synthetic analogues[1][2][4][6].
- Other names
- ulapualide atrisoxazole-based macrolidemarine macrolide toxin
02
Targets
Actin filament proteins
Beyond the preview
Go deeper on ulapualide a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulapualide a.